KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
The Malaysian Reserve

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic ...

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...
Scientific Research Publishing

Progress in Laboratory Indicators of Severe Pertussis in Children ()

Yu, X. and Li, A. (2025) Progress in Laboratory Indicators of Severe Pertussis in Children. Journal of Biosciences and ...